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A nested case-control study, including 830 cases and 992 controls from 7 cohorts, was conducted to evaluate
the association of circulating 25-hydroxyvitamin D (25(OH)D), the best indicator of vitamin D status, with risk of
endometrial cancer. Matching factors included age at blood donation, date of blood donation, and race. Conditional
logistic regression was used in the main analysis. The median concentration of 25(OH)D was slightly lower in
cases (49.4 nmol/L) than in controls (50.8 nmol/L) (P ¼ 0.08). However, there was no association between
25(OH)D concentration and disease risk, after adjustment for body mass index. Compared with the 50–<75
nmol/L 25(OH)D category, the body mass index-adjusted odds ratios and 95% conﬁdence intervals were 1.08
(95% conﬁdence interval: 0.73, 1.57) for the <25 nmol/L category and 0.90 (95% conﬁdence interval: 0.51, 1.58)
for the  100 nmol/L category (Ptrend ¼ 0.99). Similarly null results were observed after further adjustment for other
known risk factors and in stratiﬁed analyses. Although an effect of circulating 25(OH)D at high concentrations
cannot be ruled out (the highest category of 25(OH)D was  100 nmol/L, and for stratiﬁed analyses,  75 nmol/L),
these results do not support a protective role of vitamin D against endometrial cancer.
case-control studies; endometrial neoplasms; prospective studies; vitamin D
Abbreviations: CI, conﬁdence interval; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; VDPP, Cohort
Consortium Vitamin D Pooling Project of Rarer Cancers.
Endometrial cancer is the most common gynecologic
cancer in the United States, ranking fourth among all can-
cers in women in age-adjusted incidence (1). The large in-
ternational variation in incidence rates (2) suggests that
much of the risk may be modiﬁable. Factors associated with
high estrogen and low progesterone levels, such as estrogen-
only hormone replacement therapy and obesity, have been
shown to increase the risk of endometrial cancer (3). How-
ever, the role of other modiﬁable factors, such as diet and
environmental exposures, has not been fully investigated.
Limited data are available regarding the association of
vitamin D with endometrial cancer risk. Exposure to ultravi-
olet B irradiation leads to induction of vitamin D precursor
synthesis in the skin and is the main source of vitamin D in
humans (4). Ecologic studies have described an inverse as-
sociation between ultraviolet B irradiation and endometrial
cancerincidencerates,suggestingaprotectiveroleofvitamin
D against endometrial cancer (5, 6). Diet (mostly through
fortiﬁcation) and supplements are also sources of vitamin D
(4). A recent review of the only 3 case-control studies that
have examined the association between dietary intake of vi-
tamin D and risk of endometrial cancer (7–9) concluded that
the evidence available did not support an association but that
it was too limited to draw ﬁrm conclusions (10).
36 Am J Epidemiol 2010;172:36–46Conversion of 25-hydroxyvitamin D (25(OH)D) to 1,25-
dihydroxyvitamin D (1,25(OH)2D), the active vitamin D
metabolite, occurs in the endometrium (11, 12), although
the main site of conversion is the kidney (4). In addition,
endometrial tissue expresses the vitamin D receptor (12,
13), a 1,25(OH)2D-activated nuclear transcription factor
that regulates the production of proteins involved in cell
proliferation and differentiation (14). These data support
the hypothesis that vitamin D plays a role in the etiology
of endometrial cancer. 25(OH)D is considered the best in-
dicator of vitamin D status, because it measures vitamin D
resulting from both ultraviolet B exposure and dietary/
supplement intake and because it has a longer half-life
(2–3 weeks) than 1,25(OH)2D (4–6 hours) (15–17). Because
no epidemiologic study to date has examined the hypothesis
that circulating 25(OH)D is inversely related to risk of
endometrial cancer, a case-control study nested within
6 cohorts in the United States and 1 in Shanghai, China,
was conducted to examine this hypothesis as part of the
Cohort Consortium Vitamin D Pooling Project of Rarer
Cancers (VDPP).
MATERIALS AND METHODS
Study design and population
A detailed description of the overall methods of the
VDPP and participating cohorts is provided elsewhere in
this issue (18). All VDPP cohorts that included women (7
out of 10) participated in the nested case-control study of
endometrial cancer: CLUE; the Cancer Prevention Study II
Nutrition Cohort (CPS-II); the Multiethnic Cohort Study
(MEC); the Nurses’ Health Study (NHS); the New York
University Women’s Health Study (NYU-WHS); the Pros-
tate, Lung, Colorectal, and Ovarian Cancer Screening Trial
(PLCO); and the Shanghai Women’s Health Study (SWHS)
(Table 1).
Incident cases included International Classiﬁcation of
Diseases for Oncology (ICD-O) codes 8010, 8140, 8210,
8260, 8310, 8323, 8380, 8382, 8441, 8460, 8461, 8480,
8481, 8560, and 8570. In situ tumors, as well as Mullerian
tumors, stromal tumors, and sarcomas, were excluded. Case
ascertainment methods for each cohort are summarized
(18).
Control selection was done by using incidence density
sampling. Individually matched controls were selected from
the parent cohort among women who were free of cancer at
the date of diagnosis of the case (index date) and who had
not had a hysterectomy at the index date (except for the
CLUE cohort that did not collect data on hysterectomy).
Matching factors included age at blood donation (61 year,
except for CLUE and the Shanghai Women’s Health Study
(62 years)), date of blood donation (61 month, except for
the NYU-WHS (63 months)), and race (white, black,
Asian, other). All cohorts also matched on menopausal sta-
tus at blood donation.
Out of the total of 843 cases initially identiﬁed, 11 were
excluded because of ineligible histology and 2 because the
date of diagnosis was before the date of blood donation.
Thus, this analysis includes 830 cases and 992 controls
(a 1:1 case:control ratio was used, except for the Nurses’
Health Study, which used a 1:2 ratio). Histologic conﬁrma-
tion was obtained for 97% of the cases.
Measurement of circulating 25(OH)D
As reported elsewhere (18), all serum or plasma samples
were assayed for 25(OH)D at Heartland Assays, Inc. (Ames,
Iowa) by a direct, competitive chemiluminescence immuno-
assay by using the DiaSorin LIAISON 25 OH Vitamin D
TOTAL Assay (19, 20). Quality control procedures are de-
scribed (18). The inter- and intrabatch coefﬁcients of varia-
tion using masked National Institute of Standards and
Technology samples were 12.7% and 9.3% for samples at
level 1 (~60 nmol/L) and 13.6% and 11.0% for samples at
Table 1. Characteristics of Participants, by Cohort, in the Investigation of Endometrial Cancer
Within the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers
Cohort
No.
of
Cases
No.
of
Controls
Time From Blood
Collection to Cancer
Diagnosis, median
years (interquartile
range)
Circulating 25(OH)D, median nmol/L
(interquartile range)
Cases Controls
CLUE 192 192 10.0 (4.8–14.2) 51.9 (39.4–68.4) 56.8 (44.0–71.1)
CPS-II 51 51 2.2 (1.2–3.2) 60.8 (46.8–77.8) 63.5 (46.0–78.9)
MEC 39 39 1.4 (0.6–2.4) 58.0 (41.5–72.5) 61.3 (30.3–77.8)
NHS
a 163 325 7.2 (4.2–10.6) 56.3 (37.2–68.5) 52.8 (39.7–69.0)
NYU-WHS 139 139 10.7 (5.9–13.1) 41.9 (28.8–60.0) 46.7 (31.1–63.0)
PLCO 147 147 2.6 (0.6–4.7) 51.3 (39.7–65.2) 52.1 (37.1–64.8)
SWHS 99 99 4.7 (2.1–6.6) 29.9 (22.7–41.6) 33.4 (25.3–41.6)
Total 830 992 5.5 (2.3–10.5) 49.4 (34.6–66.4) 50.8 (36.7–67.1)
Abbreviations: CPS-II, Cancer Prevention Study II Nutrition Cohort; MEC, Multiethnic Cohort
Study; NHS, Nurses’ Health Study; NYU-WHS, New York University Women’s Health Study;
25(OH)D, 25-hydroxyvitamin D; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screen-
ing Trial; SWHS, Shanghai Women’s Health Study.
a A 1:2 case:control ratio was used for the NHS.
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quality control samples provided by each cohort, the median
interbatch coefﬁcient of variation was 13.2% (range: 4.8%–
17.0%), and the median intrabatch coefﬁcient of variation
was 9.9% (range: 3.8%–16.4%).
Statistical analysis
The statistical analysis was conducted following the gen-
eral approach and speciﬁc methods approved by the VDPP
Steering Committee (18). Aspects of the analysis speciﬁc to
the endometrial cancer study are described here. For the
main analysis, 25(OH)D concentrations were grouped in
a priori deﬁned, clinically relevant, categories (<25.0,
25.0–<37.5, 37.5–<50.0, 50.0–<75.0, 75.0–<100.0
and  100 nmol/L). The 50–<75 nmol/L category was used
as the referent category. Because of the small number of
subjects in the top category ( 100 nmol/L), the two top
categories were combined ( 75 nmol/L) for stratiﬁed and
subgroup analyses. Analyses were also conducted after clas-
sifying women into 25(OH)D quartiles using cohort- and
season-speciﬁc cutpoints, with the lowest quartile as refer-
ent category. In these analyses, seasons were deﬁned as
winter (December to May) or summer (June to November).
Circulating 25(OH)D was also analyzed as a natural log-
transformed continuous variable.
The seasonal variations in concentrations of 25(OH)D
were taken into account in various ways: 1) by matching
on date of blood draw and taking the matching into consid-
eration in the statistical analysis; 2) by conducting analyses
on quartiles using season-speciﬁc cutpoints; and 3) by con-
ductinganalysesusingresiduals fromregressionof25(OH)D
on week of the year, in an attempt to take into account the
gradual nature of changes in concentrations of 25(OH)D
over the year better than by adjusting for season (18).
The conditional logistic regression model was used for
the main analysis to take into account the matched design.
Because a comparison of conditional and unconditional lo-
gistic regression models using the full dataset showed that
the odds ratios obtained by the two methods were nearly
identical, stratiﬁed and subgroup analyses were conducted
using the unconditional logistic regression model and
adjusting for the matching factors (cohort, race, age (log-
transformed) and season at blood draw). The use of uncon-
ditional logistic regression preventedloss of data in analyses
stratifying by factors not used in the matching.
Data on potential confounders were collected from each
cohort and standardized as described in (18). For most vari-
ables, data collected at, or close to, blood donation were
used. For oral contraceptive and hormone replacement ther-
apy use, data up to the index date were used for the Nurses’
Health Study and the NYU-WHS, whereas data collected at,
or close to, blood donation were used for the other cohorts.
Both conditional and unconditional logistic regression
models based on the full dataset are presented adjusting
for the following known endometrial cancer risk factors:
education, menopausal status, age at menarche, parity, oral
contraceptive use, hormone replacement therapy use, body
mass index, smoking, history of high blood pressure, and
history of diabetes. To assess which factors contributed to
confounding, the change in the 25(OH)D regression coefﬁ-
cient in the conditional logistic regression model upon ad-
dition of each risk factor, one at a time, was examined.
Because only body mass index changed the 25(OH)D co-
efﬁcient by more than 10%, stratiﬁed/subgroup analyses are
presented adjusting for this factor only. Analyses adjusting
for body mass index on the continuous, log-transformed,
scale led to odds ratios qualitatively similar to those of the
analysis adjusting for body mass index as a categorical vari-
able (<25, 25–<30,  30 kg/m
2, missing), but resulted in
a smaller sample size since subjects missing body mass in-
dex data were excluded from these analyses. Therefore, re-
sults are presented adjusting for body mass index as
a categorical variable.
Analyses stratifying by known endometrial cancer risk
factors were also conducted and possible effect modiﬁcation
of the 25(OH)D-endometrial cancer association by these
factors was assessed by conducting interaction tests (18).
Because of the known biological interactions between vita-
min D and calcium, we were also interested in conducting
an analysis stratifying by calcium supplement use; however,
because of the small number of calcium supplement users,
we were only able to conduct an analysis among non users
of calcium supplements. An analysis limited to whites was
also conducted. Finally, an analysis excluding cases with
ICD-O codes other than 8010, 8140, 8380, 8382 was con-
ducted to assess a possible effect of vitamin D limited to
endometrioid tumors.
A meta-analysis assuming a random effects model was
conducted to assess between-cohort heterogeneity and to
compute overall odds ratios for endometrial cancer asso-
ciated with the low (<25 nmol/L) and high ( 75 nmol/L)
25(OH)D categories, as compared to the 50–<75 nmol/L
category (21). Cohort-speciﬁc odds ratios were computed
using the conditional logistic regression model and adjust-
ing for body mass index. Heterogeneity of cohort-speciﬁc
estimates was measured using the DerSimonian and Laird
Q statistic (22) and data are presented as forest plots.
Finally, to explore the inﬂuence of each cohort on our
results, the main analysis (using conditional logistic re-
gression and adjusting for all risk factors for endometrial
cancer listed above) was repeated excluding one cohort at
a time.
RESULTS
Table 1 describes the number of cases and controls from
each cohort and the median time between blood donation
and diagnosis for the cases, which varied from 1.4 year
(Multiethnic Cohort Study) to 10.7 years (NYU-WHS).
Among controls, a two-fold variation in median 25(OH)D
concentrations was seen across cohorts with the lowest me-
dian observed in Shanghai Women’s Health Study (33.4
nmol/L) and the highest in the Cancer Prevention Study II
Nutrition Cohort (63.5 nmol/L).
Table 2 describes characteristics of the cases and con-
trols. The median age at blood donation was 58 years and
at diagnosis 64 years. Most subjects were white (79.2%
of cases). Compared to controls, cases had younger age
38 Zeleniuch-Jacquotte et al.
Am J Epidemiol 2010;172:36–46at menarche (P ¼ 0.02) and older age at menopause
(P ¼ 0.09). Cases were also more likely than controls to
be obese (P   0.0001), to be never smokers (P ¼ 0.04)
a n dt oh a v eah i s t o r yo fh i g hb l o o dp r e s s u r e( P ¼ 0.0005)
or diabetes (P ¼ 0.003). Cases were less likely than con-
trols to report oral contraceptive use (P ¼ 0.09). Overall,
the median concentration of 25(OH)D was slightly lower
in cases than in controls (49.4 nmol/L and 50.8 nmol/L,
respectively, P ¼ 0.08), and the proportions of women
with vitamin D concentrations less than 25 nmol/L or
37.5 nmol/L were slightly higher among cases than
controls.
Table 3 presents results using the conditional logistic re-
gression model. In the crude analysis, there was some sug-
gestion that lower concentrations (<25 nmol/L) were
associated with a small increased risk of endometrial cancer
compared with the referent category of 50–<75 nmol/L
(odds ratio ¼ 1.20, 95% conﬁdence interval (CI): 0.83,
1.72) and that higher concentrations ( 100 nmol/L) were
associated with a lower risk (odds ratio ¼ 0.78, 95% CI:
0.45, 1.34); however, the test for trend was not statistically
signiﬁcant (P ¼ 0.12). After adjusting for body mass index,
odds ratios were attenuated, 1.08 (95% CI: 0.73, 1.57) for
the <25 nmol/L 25(OH)D category and 0.90 (95% CI: 0.51,
1.58) for the  100 nmol/L25(OH)D category,and therewas
no longer any evidence of a trend (P ¼ 0.99). As compared
to the body mass index-adjusted odds ratios, odds ratios
varied only slightly when adjusted for additional known
endometrial cancer risk factors. Similarly, analyses using
cohort- and season-speciﬁc quartiles, residuals, or log-
transformed 25(OH)D showed no evidence of association
with endometrial cancer risk after adjusting for body mass
index (data not shown).
There was no evidence of an association between concen-
trations of circulating 25(OH)D and endometrial cancer risk
in strata deﬁned according to season of blood draw, age at
diagnosis, lag-time between blood donation and diagnosis,
body mass index, oral contraceptive use or hormone re-
placement therapy use (Table 4). There was no evidence
of interaction for any of these factors, except hormone re-
placement therapy (P ¼ 0.04). However no consistent trend
was observed in either users (P ¼ 0.24) or non users of
hormone replacement therapy (P ¼ 0.36). No associations
were observed when analyses were limited to women who
did not use calcium supplements, white women, or women
with endometrioid tumors.
No association between circulating 25(OH)D and endo-
metrial cancer risk was observed in the meta-analysis
(Figure 1). The overall, body mass index-adjusted odds ratio
comparing the lowest concentration (<25 nmol/L) to the
referent category (50–75 nmol/L) was 1.21 (95% CI:
0.75, 1.98) while the odds ratio associated with con-
centrations  75 nmol/L was 0.98 (95% CI: 0.71, 1.35).
There was no evidence of heterogeneity between cohorts
(P ¼ 0.23 for the comparison of the <25 nmol/L and
50–75 nmol/L categories and 0.92 for the comparison of
the  75 nmol/L and 50–75 nmol/L categories). Finally,
results from analyses that excluded cohorts one at a time
were consistent, showing no statistically signiﬁcant trend
in risk across categories of 25(OH)D concentrations.
DISCUSSION
Circulating concentrations of 25(OH)D were not asso-
ciated with risk of endometrial cancer in this nested
case-control study based on seven cohorts. Though there
was some indication of a trend of decreasing risk with in-
creasing concentrations of 25(OH)D in crude analyses, no
trend was observed after adjusting for body mass index.
Obesity plays an important role in endometrial cancer eti-
ology because it is associated with increased exposure to
estrogen unopposed by progesterone, leading to increased
mitotic activity of endometrial cells and greater opportunity
for the occurrence of DNA replication errors (3). Consistent
with results from other studies (23, 24), the prevalence of
obesity was greater among cases than among controls
(Table 2). Body mass index was also inversely associated
with 25(OH)D (cohort-adjusted Spearman correlation
coefﬁcient ¼  0.16 in controls and  0.28 in cases), as
was observed in the overall population of controls included
in VDPP (25); this was expected since vitamin D tends to be
sequestered in adipose tissue (26). These associations led to
negative confounding of the 25(OH)D - endometrial cancer
risk relationship by body mass index. Such negative confound-
ing, if ignored, will lead to a spurious association as was
observed in our study prior to adjusting for body mass index.
This study is the ﬁrst to examine the association of endo-
metrial cancer risk with circulating 25(OH)D, which is con-
sidered the best marker of vitamin D status (15–17). The
results of this study are in agreement with a review of the
literature on vitamin D intake in relation to endometrial
cancer which concluded that the limited evidence available
regarding vitamin D did not support an association (10).
These studies, though, did not take into account vitamin D
obtained from ultraviolet B exposure. An ecological study
of 107 countries reported that endometrial cancer incidence
rates were higher at higher latitudes and concluded that low
ultraviolet B irradiance, which is associated with lower vi-
tamin D exposure, was associated with endometrial cancer
risk (6). However, although the authors adjusted for the pro-
portion of the population whowere overweight as well as for
some other risk factors, the observed association could be
due to ecological fallacy since control for body mass index
and other risk factors at the individual level was not
possible.
A strength of the present study was the availability of
individual data, collected prospectively, on known risk
factors for endometrial cancer. For most of these risk fac-
tors, differences between cases and controls were as ex-
pected. Hormone replacement therapy use, though, was
less common in cases than in controls. This result appears
inconsistent with the known positive association between
estrogen-only replacement therapy and endometrial cancer
risk. However, our study did not have the ability to assess
the association of this variable with disease risk because
most participating cohorts matched on use of hormone re-
placement therapy at entry. In addition, we were not able to
distinguish between estrogen-only and estrogen plus proges-
tin formulations, nor to take into account the recency of use,
both factors which impact the association of hormone re-
placement therapy with endometrial cancer risk (23, 27–29).
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Characteristic
Cases (N 5 830) Controls (N 5 992)
P Value
a
No. % Median (Interquartile Range) No. % Median (Interquartile Range)
Age at blood draw, years 58 (50–65) 58 (50–64) Matched
Age at diagnosis, years 64 (58–70)
Race
b Matched
White 657 79.2 819 82.6
Black 18 2.2 23 2.3
Asian 120 14.5 118 11.9
Other 23 2.8 26 2.6
Education
b 0.22
Less than high school 152 18.3 164 16.5
Completed high school 203 24.5 183 18.4
Vocational school 32 3.9 45 4.5
Some college 232 28.0 333 33.6
College graduate 102 12.3 136 13.7
Graduate studies 82 9.9 122 12.3
Height, cm 162.6 (157.5–167.6) 163 (157–168) 0.76
Missing 73 8.8 104 10.5
Weight, kg 70.5 (61.4–83.9) 65.8 (59–75) <0.0001
Missing 104 12.5 108 10.9
Body mass index, kg/m
2 <0.0001
<25 255 30.7 459 46.3
25–<30 229 27.6 291 29.3
 30 239 28.8 132 13.3
Missing 107 12.9 110 11.1
Age at menarche, years 12.5 (12–14) 13 (12–14) 0.02
Missing 131 15.8 138 13.9
History of full-term pregnancy 0.12
Yes 561 67.6 722 72.8
No 98 11.8 94 9.5
Missing 171 20.6 176 17.7
Ever used an oral contraceptive 0.09
Yes 254 30.6 363 36.6
No 465 56.0 522 52.6
Missing 111 13.4 107 10.8
Menopausal status
b Matched
Premenopause 235 28.36 273 27.5
Perimenopause 29 3.5 36 3.6
Postmenopause 558 67.2 680 68.5
Age at menopause, years 52 (49–53) 51 (47–53) 0.09
Missing 295 35.5 328 33.1
Ever used HRT –
c
Yes 302 36.4 409 41.2
No 420 50.6 475 47.9
Missing 108 13.0 108 10.9
Smoking status
b 0.04
Never 512 61.7 543 54.7
Table continues
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Am J Epidemiol 2010;172:36–46Because sun exposure is the main source of vitamin D,
circulating concentrations of 25(OH)D are lower in the
winter than in the summer months and it is important to
take into account such variations to avoid bias (30). In
a d d i t i o nt om a t c h i n go nd a t eo fb l o o dd r a w ,t h i si s s u e
was addressed using various statistical methods. There
Table 2. Continued
Characteristic
Cases (N 5 830) Controls (N 5 992)
P Value
a
No. % Median (Interquartile Range) No. % Median (Interquartile Range)
Former 232 28.0 325 32.8
Current 74 8.9 116 11.7
Physical activity 0.69
Sedentary 228 27.5 264 26.6
Light 163 19.6 197 19.9
Moderate 140 16.9 188 19.0
Vigorous 145 17.5 196 19.8
Missing 154 18.6 147 14.8
History of high blood pressure
b 0.0005
Yes 270 32.5 248 25.0
No 547 65.9 735 74.1
History of diabetes
b 0.003
Yes 50 6.0 30 3.0
No 760 91.6 948 95.6
Caloric intake, kcal/day 1,613 (1,276–1,993) 1,634 (1,286–2,027) 0.52
Missing 140 16.9 140 14.1
Vitamin D, IU/day 161 (98–237) 179 (105–305) 0.86
Missing 140 16.9 140 14.1
Energy-adjusted vitamin D, IU/day 179 (117–252) 197 (126–311) 0.76
Missing 140 16.9 140 14.1
Current use of multivitamins
b 0.83
Yes 243 29.3 297 29.9
No 547 65.9 652 65.7
Current use of vitamin D supplements 0.06
Yes 32 3.9 54 5.4
No 297 35.8 440 44.4
Missing 501 60.4 498 50.2
Current use of calcium supplement 0.55
Yes 170 20.5 223 22.5
No 437 52.7 514 51.8
Missing 223 26.9 255 25.7
Season of blood draw –
d
Winter 134 16.1 167 16.8
Spring 192 23.1 236 23.8
Summer 262 31.6 295 29.7
Fall 242 29.2 294 29.6
25(OH)D, nmol/L 49.4 (34.6–66.4) 50.8 (36.7–67.1) 0.08
25(OH)D, <25 nmol/L 93 11.1 88 8.9 0.12
25(OH)D, <37.5 nmol/L 255 30.4 263 26.5 0.07
Abbreviations: HRT, hormone replacement therapy; MEC, Multiethnic Cohort Study; NHS, Nurses’ Health Study; 25(OH)D, 25-hydroxyvitamin
D; NYU-WHS, New York University Women’s Health Study; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
a Wald test from conditional logistic regression, excluding subjects with missing data.
b Data were missing for <5% of subjects.
c –, matching factor for CLUE, MEC, NHS, and PLCO.
d –, matching on date of blood draw (61 month except for NYU-WHS, 63 months).
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of these analyses.
Interactions of vitamin D and vitamin D analogs with
estrogens have been reviewed (31, 32). Although, to our
knowledge, there are no data speciﬁc to the endometrium,
it has been proposed, based on an animal model of breast
cancer, that 1,25(OH)2D opposes estrogen-driven prolifera-
tion (33). In this study, the test for interaction by hormone
replacement therapy use was statistically signiﬁcant (P for
heterogeneity ¼ 0.04); however, there was no evidence of
a protective effect of vitamin D in either ever or never users
of hormone replacement therapy (Table 4). In addition, no
association was observed between circulating 25(OH)D and
risk of endometrioid endometrial cancer, a subtype strongly
associated with estrogen (34). Because of the data collection
procedures of some of the cohorts and in order to have
sufﬁcient numbers of cases, non-endometrioid subtypes
(mucinous, serous, clear cell, squamous-cell, mixed)
were excluded in this analysis but adenocarcinomas not-
otherwise -speciﬁed (ICD-O codes 8140 and 8010) (n ¼
462) were combined with endometrioid tumors (n ¼ 223).
It is therefore likely that some tumors of non-endometrioid
subtype were included. However, since endometrioid tu-
mors represent about 80% of all endometrial carcinomas,
it is unlikely that an association was missed in this sub-
group. Because of small numbers, the association of
25(OH)D with other subtypes of endometrial cancer could
not be examined.
The concentrations of circulating 25(OH)D observed in
this study were similar to concentrations observed in women
in the United States (35). Few women, though, had high
concentrations and the highest category that could be stud-
ied was was  100 nmol/L, and for stratiﬁed and subgroup
analyses,  75 nmol/L. Therefore, conclusions cannot be
drawn regarding the potential protective effect of higher
concentrations of 25(OH)D. However, although a threshold
effect is possible, the complete lack of a dose-response re-
lationship in this study argues against a protective role of
vitamin D.
Strengths of this study include the prospective assessment
of vitamin D status and possible confounders, the inclusion
of women living in a wide range of latitudes, a large number
of cases and the use of the same laboratory to assay all
samples. Only one serum/plasma sample was used for each
participant which leads to some measurement error regard-
ing the exposure of interest, i.e. the long-term average cir-
culating level of 25(OH)D. However, circulating
concentrations of 25(OH)D appear relatively stable when
collected during the same season. A pilot study conducted
in the NYU-WHS using the same assay in the same labora-
tory found an intraclass correlation coefﬁcient of 0.78 (95%
CI: 0.64, 0.88) in 30 healthy women who contributed three
samples each at yearly intervals (unpublished data). Like-
wise, in the Nurses’ Health Study, the intraclass correlation
coefﬁcient for 25(OH)D was 0.72 (95% CI: 0.62, 0.80) in 71
women over a 2–3 year period using a similar assay (un-
published data). These results are comparable to those ob-
served in 144 middle-aged men for whom the Pearson
correlation between samples collected 4 years apart was
0.70 (36). Such temporal reliability compares favorably to
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Am J Epidemiol 2010;172:36–46Table 4. Odds Ratios and 95% Conﬁdence Intervals for the Association Between Circulating 25(OH)D and Risk of Endometrial Cancer Within the Cohort Consortium Vitamin D Pooling
Project of Rarer Cancers With Stratiﬁed/Subgroup Analyses
a
Circulating 25(OH)D, nmol/L
Ptrend
<25.0 25.0–<37.5 37.5–<50.0 50.0–<75.0 ‡75.0
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR 95%
CI
All 93 88 162 170 163 224 293 349 119 161
Crude
b 1.22 0.86, 1.75 1.11 0.84, 1.46 0.85 0.66, 1.11 1.0 Referent 0.85 0.64, 1.14 0.11
Adjusted
c 1.02 0.70, 1.47 0.93 0.70, 1.24 0.79 0.61, 1.04 1.0 Referent 0.93 0.69, 1.24 0.89
Adjusted
d 0.98 0.67, 1.44 0.91 0.67, 1.22 0.80 0.61, 1.05 1.0 Referent 0.93 0.69, 1.26 0.73
Season
c
December–May 54 55 0.85 0.49, 1.48 77 87 0.82 0.52, 1.31 55 77 0.81 0.50, 1.30 83 107 1.0 Referent 27 49 0.67 0.37, 1.21 0.99
June–November 39 33 1.16 0.68, 1.98 85 83 1.01 0.69, 1.47 108 147 0.79 0.57, 1.08 210 242 1.0 Referent 92 112 1.02 0.72, 1.44 0.92
Age at diagnosis,
years
c
 58 31 27 0.94 0.46, 1.91 43 48 0.70 0.38, 1.28 38 55 0.68 0.39, 1.21 71 71 1.0 Referent 25 43 0.72 0.38, 1.37 0.87
>58–64 28 24 1.38 0.67, 2.84 34 45 0.89 0.49, 1.60 34 50 0.71 0.40, 1.27 63 82 1.0 Referent 32 29 1.50 0.80, 2.81 0.61
>64–70 17 19 0.86 0.38, 1.97 41 43 0.85 0.48, 1.52 46 58 0.90 0.53, 1.51 77 96 1.0 Referent 31 48 0.81 0.45, 1.45 0.91
>70 17 18 0.92 0.41, 2.09 44 34 1.45 0.81, 2.59 45 61 0.86 0.52, 1.42 82 100 1.0 Referent 31 41 0.86 0.48, 1.55 0.45
Lagtime, years
c
 5 44 42 0.98 0.57, 1.68 72 77 0.82 0.53, 1.26 73 88 0.78 0.52, 1.17 145 151 1.0 Referent 53 78 0.77 0.50, 1.20 0.97
>5 49 46 1.07 0.64, 1.79 90 93 1.04 0.70, 1.54 90 136 0.81 0.57, 1.15 148 198 1.0 Referent 66 83 1.08 0.72, 1.62 0.84
Body mass index,
kg/m
2c
<25 24 47 0.81 0.44, 1.48 31 66 0.76 0.45, 1.29 48 94 0.81 0.52, 1.26 98 162 1.0 Referent 54 90 0.98 0.63, 1.52 0.31
25–<30 27 20 1.42 0.70, 2.86 51 61 0.98 0.59, 1.64 49 66 0.99 0.61, 1.61 76 102 1.0 Referent 26 42 0.85 0.47, 1.53 0.38
 30 38 15 1.05 0.46, 2.39 63 28 1.13 0.60, 2.12 44 37 0.62 0.34, 1.16 72 38 1.0 Referent 22 14 0.79 0.35, 1.79 0.59
Oral contraceptive
use
c
Never 60 50 1.09 0.67, 1.77 90 101 0.75 0.50, 1.11 96 116 0.84 0.59, 1.21 159 174 1.0 Referent 60 81 0.83 0.55, 1.27 0.96
Ever 27 32 0.88 0.45, 1.72 52 55 1.15 0.69, 1.91 44 81 0.75 0.47, 1.22 87 131 1.0 Referent 44 64 1.10 0.67, 1.80 0.71
HRT use
c
Never 76 57 1.27 0.78, 2.07 86 98 0.81 0.53, 1.25 93 102 1.10 0.74, 1.64 118 145 1.0 Referent 47 73 0.79 0.49, 1.28 0.36
Ever 13 25 0.65 0.31, 1.37 54 59 0.97 0.61, 1.55 48 98 0.55 0.35, 0.84 133 157 1.0 Referent 54 70 0.95 0.61, 1.47 0.24
No calcium
supplements
use
c
41 35 1.21 0.69, 2.10 76 90 0.85 0.57, 1.26 94 114 0.89 0.62, 1.27 165 192 1.0 Referent 61 83 0.87 0.58, 1.30 0.81
White race
c 46 53 0.96 0.61, 1.51 116 114 1.09 0.79, 1.50 133 190 0.79 0.60, 1.06 255 317 1.0 Referent 107 145 0.93 0.68, 1.27 0.91
Endometrioid
tumors
c
93 88 1.01 0.70, 1.47 162 170 0.93 0.70, 1.24 163 224 0.79 0.61, 1.04 293 349 1.0 Referent 119 161 0.93 0.69, 1.24 0.89
Abbreviations: CI, conﬁdence interval; HRT, hormone replacement therapy; 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio.
a All P values for heterogeneity > 0.14, except for HRT (P ¼ 0.04).
b Unconditional logistic regression model, adjusted for matching factors.
c Unconditional logistic regression model, adjusted for matching factors and body mass index (<25, 25–<30,  30 kg/m
2, missing).
d Unconditional logistic regression model, adjusted for education (less than high school, completed high school, vocational school, some college, college graduate, graduate studies, missing), menopausal status (pre-, peri-, postmenopause, missing),
age at menarche (<13,  13 years of age, missing), parity (0, 1, 2, 3,  4, missing), oral contraceptive use (never, ever, missing), HRT use (never, ever, missing), smoking (never, former, current, missing), history of high blood pressure (yes, no, missing),
history of diabetes (yes, no, missing), and body mass index (<25, 25–<30,  30 kg/m
2, missing).
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Figure 1. Forest plots for the meta-analysis of the association between circulating 25(OH)D and risk of endometrial cancer within the Cohort Consortium Vitamin D Pooling Project of Rarer
Cancers. Risk estimates, by cohort, are shown for subjects with circulating 25(OH)D concentrations of <25 nmol/L (A) and  75 nmol/L (B) compared with the referent group (50–<75 nmol/L).
Odds ratios and 95% conﬁdence intervals were derived from conditional logistic regression models adjusted for body mass index. The boxes show the odds ratios, the bars show the 95%
conﬁdenceintervals,and thesizeof eachbox isinverselyproportionalto thevarianceof thelogoddsratioestimate ineachcohort.Theoverall estimates (diamonds) comefrom ameta-analysis
with random-effects modeling. CPS-II and MEC data are not included in the low versus referent category forest plot (A) because of highly unstable risk estimates. CI, conﬁdence interval; CPS-
II, Cancer Prevention Study II Nutrition Cohort; MEC, Multiethnic Cohort Study; NHS, Nurses’ Health Study; NYU-WHS, New York University Women’s Health Study; 25(OH)D, 25-
hydroxyvitamin D; OR, odds ratio; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SWHS, Shanghai Women’s Health Study.
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:
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4
6thatofotherbiomarkersthathavebeenfoundtobeassociated
with disease, such as circulating estrogens (e.g., intraclass
correlation coefﬁcient in the 0.50–0.70 range for estradiol
over a 2–3 year period (37, 38)), which have been consis-
tently found to be associated with breast cancer risk (39).
In conclusion, after taking into account the effect of body
mass index, circulating concentrations of 25(OH)D do not
appear to be associated with risk of endometrial cancer.
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